Bhavana Pothuri, MD
The addition of 3 PARP inhibitors to the landscape of ovarian cancer—rucaparib (Rubraca), olaparib (Lynparza), and niraparib (Zejula)—have led to practice-changing, targeted treatment options for patients whose diseases progress on chemotherapy. The recent FDA approvals of olaparib and niraparib in the maintenance settings, specifically, have opened a new door where previously there were no such therapies available.
on Treatment Options in Ovarian Cancer, Pothuri discussed the available PARP inhibitors and ongoing trials further investigating these agents in ovarian cancer.
OncLive: What did you discuss regarding PARP inhibitors in ovarian cancer?
: It is a very exciting time for PARP inhibitors. The PARP inhibitors are a class of targeted agents that are utilized in ovarian cancer, and this is important because ovarian cancer accounts for only about 20% of gynecologic malignancies, but it accounts for over 50% of gynecologic cancer deaths. There is a real need for new agents, and the PARP inhibitors are a class of new agents for which we now have approvals with multiple different drugs.
... to read the full story